Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer
Molecular Pharmaceutics · 02.12.2024 · 21 (12) · 5960-5988
DOI: 10.1021/acs.molpharmaceut.4c00801 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 19.11.2024. Verfasst von Sreejith Thrivikraman Nair und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Nanomedicine, Carcinoma, Pancreatic Ductal, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 263 Literaturangaben. Gefördert von: Indian Council of Medical Research, Amrita Vishwa Vidyapeetham University.
Abstract (Originalsprache)
Tumor heterogeneity poses a significant challenge in cancer therapy. To address this, we analyze pharmacotherapeutic challenges by categorizing them into static and dynamic barriers, reframing these challenges to improve drug delivery, efficacy, and the development of controlled-release nanomedicines (CRNMs). This pathophysiology-driven approach facilitates the design of novel therapeutics tailored to overcome obstacles in pancreatic ductal adenocarcinoma (PDAC) using nanotechnology. Advanced biomaterials in nanodrug delivery systems offer innovative solutions by combining controlled release, stimuli sensitivity, and smart design strategies. CRNMs are engineered to modulate spatiotemporal signaling and control drug release in PDAC, where resistance to conventional therapies is particularly high. This review explores pharmacokinetic considerations for nanomedicine design, RNA interference (RNAi) for stromal modulation, and the development of targeted nanomedicine strategies. Additionally, we highlight the limitations of current animal models in capturing the complexities of PDAC and discuss notable clinical failures, such as PEGylated hyaluronidase (Phase III HALO 109-301 trial) and evofosfamide (TH-302) with gemcitabine (MAESTRO trial), underscoring the need for improved models and treatment strategies. By targeting pathways like Notch and Hedgehog and incorporating stimuli-sensitive and pathway-modulating agents, CRNMs offer a promising avenue to enhance drug penetration and efficacy, reshaping the paradigm of pancreatic cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala 682041, India.
- Department of Medical Oncology and Hematology, School of Medicine, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala 682041, India.
- Department of Veterinary Medicine, Central Animal Facility, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala 682041, India.
- Department of Nuclear Medicine, Amrita School of Medicine, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala 682041, India.
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala 682041, India.
ORCID-Profile: Sreejith Thrivikraman Nair, Kaladhar Kamalasanan
Förderung
- Indian Council of Medical Research
- Amrita Vishwa Vidyapeetham University
Zitieren
APA
Nair, S. T., Abhi, C., Kamalasanan, K., Pavithran, K., Unni, A. R., Sithara, M. S., Sarma, M., & Mangalanandan, T. S. (2024). Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. Molecular Pharmaceutics, 21(12), 5960-5988. https://doi.org/10.1021/acs.molpharmaceut.4c00801
Vancouver
Nair ST, Abhi C, Kamalasanan K, Pavithran K, Unni AR, Sithara MS, et al. Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. Molecular Pharmaceutics. 2024;21(12):5960-5988. doi:10.1021/acs.molpharmaceut.4c00801
BibTeX
@article{Nair2024,
author = {Nair, Sreejith Thrivikraman and Abhi, C and Kamalasanan, Kaladhar and Pavithran, K and Unni, Ashok R and Sithara, M S and Sarma, Manjit and Mangalanandan, T S},
title = {Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {12},
pages = {5960--5988},
doi = {10.1021/acs.molpharmaceut.4c00801}
}
EUVIMED